ACTRN12623000476639已完成1 期
Phase 1, Randomized, Placebo-controlled, Double-blind, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability and Pharmacokinetics of NB-4746 in Healthy Volunteers
ura Bio Inc.0 个研究点目标入组 52 人开始时间: 2023年5月11日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 52
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 65 Years（—）
- 性别
- All
入选标准
- •Male and post-menopausal females aged >/=18 years and < /=65 years old at the time of signing informed consent.
- •- Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring (ECG).
- •- Nonsmoker and/or ex-smoker who has discontinued smoking and/or the use of nicotine containing products for at least 3 months prior to first dose of study drug.
- •- Body mass index within the range 18 to 30 kg/m2 inclusive.
- •- Females must be either postmenopausal for >/=1 year (or with FSH >/=40 mIU/mL at screening if postmenopausal for < 1 year) or surgically sterile (having undergone bilateral tubal ligation, hysterectomy, or bilateral oophorectomy) for at least 6 months. However, to protect against the transfer of the study drug in any bodily fluids, male partners of female subjects (whether postmenopausal or surgically sterile) must use a barrier form (e.g., condom) of contraception until the end of the study visit (EOS) or 7 days after the last dose of study drug in case of early termination.
- •- Males with female partners of childbearing potential will agree to use barrier contraceptive (i.e., condom) and their female partners must use a highly effective method of contraception from screening to 90 days after the last dose of study drug. Males must also refrain from sperm donations during this time period. Males who are abstinent will not be required to use a contraceptive method unless they become sexually active. Males in a same sex relationship must also use a barrier form of contraception against the transfer of the study drug in any bodily fluids until the end of the study visit (EOS) or 7 days after the last dose of study drug in case of early termination.
排除标准
- •- History or presence of significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention; or interfering with the interpretation of data.
- •- Subjects with a history of pancreatitis or with prior cholecystectomy.
- •- Any significant chronic medical illness, as determined by the investigator.
- •- Mentally or legally incapacitated, has significant emotional problems at screening or expected during the conduct of the study, or has a history of a clinically significant psychiatric disorder within the last 5 years. Note: normal healthy volunteers who have had situational depression may be enrolled in the study at the discretion of the Investigator.
- •- The subject has a history of severe drug allergy or hypersensitivity or food allergy, including anaphylaxis.
- •- The subject has had surgery or trauma with significant blood loss within the last 3 months prior to the first dose of study drug.
- •- The subject has donated more than 1 unit (500 mL) of blood within 4 weeks prior to the first dose of study drug. .
- •- Abnormal vital signs that are considered to be clinically significant by the investigator.
- •- Lymphoma, leukemia, or any malignancy within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years. Fully resected basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) with no evidence of recurrence for 1 year are permitted.
- •- Breast cancer within the past 10 years.
- •- Clinically significant laboratory abnormality at the screening visit or before the administration of the first dose of study drug.
- •- Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of asymptomatic gallstones).
- •- QTcF interval (QT with Fredericia’s correction) > 450 msec in males and > 470 msec in females (based on the mean of triplicate measurements taken at screening).
- •- Females of childbearing potential, irrespective of contraceptive measures taken.
- •- Inability to tolerate oral medications.
- •- Past or intended use of over-the-counter or prescription medication (including herbal medications) within 14 days before dosing.
- •- Live vaccine(s) within 1 month before Screening or plans to receive such vaccines during the study.
- •- Treatment with biologic agents (such as monoclonal antibodies including marketed drugs) within 3 months or 5 half-lives (whichever is longer) before dosing.
- •- Current participation in any other investigational drug study or receipt of an investigational drug within 30 days or 5 half-lives (whichever is longer) before Screening.
- •- Positive prestudy drug or alcohol screen.
- •- Positive human immunodeficiency virus (HIV) or hepatitis C antibody test (HCV), or hepatitis B surface antigen (HBsAg) at screening or 3 months before enrollment.
- •- Regular alcohol consumption within 6 months before the study defined, current evidence of substance dependence or self-reported alcoholic intake > 2 drinks/day for female subjects and > 3 drinks/day for male subjects.
- •- Use of tobacco products (e.g., cigarettes, e-cigarettes, cigars, smokeless tobacco) confirmed by a positive cotinine test on Day -1.
- •- Regular use of known drugs of abuse or a history of drug abuse within 12 months prior to sc
研究者
相似试验
已完成
不适用
Phase 1, randomized, placebo controlled, double blind, single dose-escalation study assessing the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous IQNLF in healthy subjects.AnthraxBacillus anthracis10004018NL-OMON36585IQ Therapeutics36
已完成
1 期
Phase I study of oral artesunate in colorectal cancerColorectal adenocarcinomaMalignant neoplasm of colonCancerISRCTN05203252St George's, University of London (UK)22
招募中
1 期
A clinical Trial to study the safety, immunogenicity and tolerability of a tetravalent rotavirus vaccine in Indian infants.CTRI/2009/091/001080Shantha Biotechnics Limited, Hyderabad90
已完成
1 期
A study to investigate how ENTR-601-44 behaves in the body, the safety and how well tolerated different increasing amounts of the drug ENTR-601-44 are when given to healthy male volunteersHealthy volunteersISRCTN36174912Entrada Therapeutics, Inc.32
招募中
1 期
A Phase 1 Study of MAXONA Pharmaceuticals MAX-001 healthy subjects for the evaluation of safety, tolerability, and drug concentrations in progressively increasing single and multiple daily dose levelsVarious pain indicationsAnaesthesiology - Pain managementACTRN12622001351707George Clinical Pty Ltd60